Loading
A phase 2 trial of Valemetostat Tosylate in peripheral T-cell lymphomas and non-Hodgkin lymphoma, run by Daiichi Sankyo, active and no longer recruiting.
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) is a phase 2 interventional study registered as NCT04703192 by Daiichi Sankyo, with 155 participants enrolled, started 2021-06-03 and due to reach its primary completion in 2023-05-10. Interventions recorded: Valemetostat Tosylate. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
155 enrolled.
95% CI 34.6 to 53.1; Figures from the ClinicalTrials.gov results section (first posted 2024-07-22), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)primary | Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) | 119 | 43.7% | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daiichi Sankyo, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/